Search Results

Invectys, Inc., a clinical-stage immuno-oncology company developing novel therapies for the treatment of advanced cancers, today announces it has initiated the clinical trial of its lead CAR-T program, IVS-3001, in solid tumors.

Invectys, Inc. “Invectys” announced that Praveen Tyle, Ph.D., President and CEO of Invectys, will participate in the 2023 edition of the JP Morgan Healthcare Meeting on January 9-12, 2023.

Invectys, Inc. and CTMC today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 1/2a clinical study of IVS-3001, Invectys’s lead engineered human leukocyte antigen A (HLA-G) targeting chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors.

Invectys, Inc. and CTMC today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 1/2a clinical study of IVS-3001, Invectys’s lead engineered human leukocyte antigen A (HLA-G) targeting chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors.

Invectys, Inc. of Houston, Texas, announced the appointment of Francois Lescure, Ph.D., as General Manager of its Paris-based R&D subsidiary, Invectys SAS, to succeed the co-founder, Dr. Pierre Langlade-Demoyen, who is stepping back from active management of Invectys SAS.

Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to meet the needs of cancer patients, announced that Timothy Papp is joining Invectys as its Chief Financial Officer.

Invectys is one of only a few companies investigating HLA-G, a natural immune checkpoint inhibitor, for solid tumors.

Invectys, Inc. (Invectys), The University of Texas MD Anderson Cancer Center and the Cell Therapy Manufacturing Center (CTMC), a joint venture between MD Anderson and National Resilience, Inc., today announced a strategic collaboration to jointly develop a reliable, compliant and scalable process for human leukocyte antigen (HLA)-G targeted chimeric antigen receptor (CAR) T cell therapy for solid tumors.

Praveen Tyle, Ph.D., Invectys Inc. President and CEO will provide an outlook for the business and its pipeline of treatments for cancer diseases and present an overview of all of Invectys’ projects to date on January 10th.

Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to meet the needs of cancer patients, today announced the appointment of Jian Cao, Ph.D., as Vice President, Pharmaceutical Development.